Literature DB >> 32128726

Modeling Heterogeneity in Patients' Preferences for Psoriasis Treatments in a Multicountry Study: A Comparison Between Random-Parameters Logit and Latent Class Approaches.

Marco Boeri1, Daniel Saure2, Alexander Schacht2, Elisabeth Riedl3, Brett Hauber4.   

Abstract

BACKGROUND: Either a random-parameters logit (RPL) or latent class (LC) model can be used to model or explain preference heterogeneity in discrete-choice experiment (DCE) data. The former assumes continuous distribution of preferences across the sample, while the latter assumes a discrete distribution. This study compared RPL and LC models to explore preference heterogeneity when analyzing patient preferences for psoriasis treatments.
METHODS: Using DCE data collected from respondents with moderate-to-severe plaque psoriasis, we calculated and compared preference weights derived from RPL and LC models. We then compared how RPL and LC explain preference heterogeneity by exploring differences across subgroups defined by observed characteristics (i.e., country, age, gender, marital status, and psoriasis severity).
RESULTS: While RPL and LC models resulted in the same mean preference weights, different preference-heterogeneity patterns emerged from the two approaches. In both models, country of residence and self-reported disease severity could be linked to systematic differences in preferences. The RPL also identified gender and marital status, but not age, as sources of heterogeneity; the LC membership probability model indicated that age was a significant factor, but not gender or marital status.
CONCLUSIONS: Using data from a psoriasis patient survey to compare two widely used methods for exploring heterogeneity identified differences in results between stated-preferences: subgroup analysis in the RPL model and inclusion of subgroup characteristics in the class membership probability function of the LC model. Researchers should model data using the most adaptable approach to address the initial study question.

Entities:  

Mesh:

Year:  2020        PMID: 32128726     DOI: 10.1007/s40273-020-00894-7

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  5 in total

1.  Myeloma Patient Value Mapping: A Discrete Choice Experiment on Myeloma Treatment Preferences in the UK.

Authors:  Simon Fifer; Jayne Galinsky; Sarah Richard
Journal:  Patient Prefer Adherence       Date:  2020-07-28       Impact factor: 2.711

2.  Long-Acting Injection and Implant Preferences and Trade-Offs for HIV Prevention Among South African Male Youth.

Authors:  Elizabeth T Montgomery; Erica N Browne; Millicent Atujuna; Marco Boeri; Carol Mansfield; Siyaxolisa Sindelo; Miriam Hartmann; Sheily Ndwayana; Linda-Gail Bekker; Alexandra M Minnis
Journal:  J Acquir Immune Defic Syndr       Date:  2021-07-01       Impact factor: 3.771

3.  Discrete choice experiment (DCE) to quantify the influence of trial features on the decision to participate in cystic fibrosis (CF) clinical trials.

Authors:  Rebecca Anne Dobra; Marco Boeri; Stuart Elborn; Frank Kee; Susan Madge; Jane C Davies
Journal:  BMJ Open       Date:  2021-03-02       Impact factor: 2.692

4.  Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis.

Authors:  David A Walsh; Marco Boeri; Lucy Abraham; Jo Atkinson; Andrew G Bushmakin; Joseph C Cappelleri; Brett Hauber; Kathleen Klein; Leo Russo; Lars Viktrup; Dennis Turk
Journal:  Eur J Pain       Date:  2022-01-08       Impact factor: 3.651

5.  Artificial intelligence in breast cancer screening: primary care provider preferences.

Authors:  Nathaniel Hendrix; Brett Hauber; Christoph I Lee; Aasthaa Bansal; David L Veenstra
Journal:  J Am Med Inform Assoc       Date:  2021-06-12       Impact factor: 4.497

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.